UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 111

Sortiert nach

Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia

The American journal of cardiology, 2015-05, Vol.115 (9), p.1212-1221

2015

Volltextzugriff (PDF)

Population PK/PD modeling of low‐density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti‐PCSK9 monoclonal antibody

CPT: pharmacometrics and systems pharmacology, 2023-12, Vol.12 (12), p.2013-2026

2023

Volltextzugriff (PDF)

Genome-wide pharmacogenetics of anti-drug antibody response to bococizumab highlights key residues in HLA DRB1 and DQB1

Scientific reports, 2022-03, Vol.12 (1), p.4266-4266, Article 4266

2022

Volltextzugriff (PDF)

Superselective Chemoembolization of HCC: Comparison of Short-term Safety and Efficacy between Drug-eluting LC Beads, QuadraSpheres, and Conventional Ethiodized Oil Emulsion

Radiology, 2016-02, Vol.278 (2), p.612

2016

Volltextzugriff (PDF)

MET Receptor Sequence Variants R970C and T992I Lack Transforming Capacity

Cancer research (Chicago, Ill.), 2010-08, Vol.70 (15), p.6233-6237

2010

Volltextzugriff (PDF)

Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites

Journal of clinical pharmacology, 2021-10, Vol.61 (10), p.1311-1323

2021

Volltextzugriff (PDF)

Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites

Journal of clinical pharmacology, 2022-04, Vol.62 (4), p.505-519

2022

Volltextzugriff (PDF)

A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia

Clinical cancer research, 2024-02, Vol.30 (3), p.489

2024

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of bococizumab, a monoclonal antibody to PCSK9, after single subcutaneous injection at three sites [NCT 02043301]

Cardiovascular therapeutics, 2017-10, Vol.35 (5), p.n/a

2017

Volltextzugriff (PDF)

Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies

BioDrugs : clinical immunotherapeutics, biopharmaceuticals, and gene therapy, 2019-10, Vol.33 (5), p.571-579

2019

Volltextzugriff (PDF)

Comparative Pharmacokinetics and Pharmacodynamics of Bococizumab Following a Single Subcutaneous Injection Using Drug Substance Manufactured at Two Sites or Administration via Two Different Devices

Clinical pharmacology in drug development, 2019-01, Vol.8 (1), p.40-48

2019

Volltextzugriff (PDF)

Quantitative PK–PD Model-Based Translational Pharmacology of a Novel Kappa Opioid Receptor Antagonist Between Rats and Humans

The AAPS journal, 2011-12, Vol.13 (4), p.565-575

2011

Volltextzugriff (PDF)

Improved preclinical cardiovascular therapeutic indices with long-term inhibition of norepinephrine reuptake using reboxetine

Toxicology and applied pharmacology, 2012-11, Vol.264 (3), p.343-350

2012

Volltextzugriff (PDF)

Dose-escalating study of the pharmacokinetics and tolerability of fesoterodine in children with overactive bladder

Journal of pediatric urology, 2012-08, Vol.8 (4), p.336-342

2012

Volltextzugriff (PDF)

Pharmacokinetic/pharmacodynamic analysis of β-amyloid response following modulation of the gamma secretase enzyme

Alzheimer's & dementia, 2010-07, Vol.6 (4), p.S544-S544

2010

Volltextzugriff (PDF)

Pharmacokinetic and pharmacodynamic evaluation of PF-04360365, a humanized monoclonal anti-amyloid antibody, in young and aged cynomolgus monkeys

Alzheimer's & dementia, 2009-07, Vol.5 (4), p.P423-P423

2009

Volltextzugriff (PDF)

PF-04447943, a novel PDE9A inhibitor, increases cGMP levels in cerebrospinal fluid: Translation from non-clinical species to healthy human volunteers

Alzheimer's & dementia, 2009-07, Vol.5 (4), p.P330-P331

2009

Volltextzugriff (PDF)

Aβ variability and effect of gamma secretase inhibition on cerebrospinal fluid levels of Aβ in healthy volunteers

Alzheimer's & dementia, 2009-07, Vol.5 (4), p.P252-P253

2009

Volltextzugriff (PDF)

Lack of critical involvement of endothelial nitric oxide synthase in vascular nitrate tolerance in mice

British journal of pharmacology, 2002-01, Vol.135 (2), p.299-302

2002

Volltextzugriff (PDF)

H3 receptor antagonism increases methylhistamine levels in the cerebrospinal fluid of dogs and healthy human volunteers

Alzheimer's & dementia, 2009-07, Vol.5 (4), p.P254-P255

2009

Volltextzugriff (PDF)

Pharmacodynamics of in vivo nitroglycerin tolerance in normal conscious rats: effects of dose and dosing protocol

Pharmaceutical research, 2004-01, Vol.21 (1), p.114-120

2004

Volltextzugriff (PDF)

Prazosin Potentiates the Acute Hypotensive Effects of Nitroglycerin but Does Not Attenuate Nitrate Tolerance in Normal Conscious Rats

Journal of cardiovascular pharmacology, 2004-03, Vol.43 (3), p.341-346

2004

Volltextzugriff (PDF)

Abstract CT108: First-in-patient study of the GDF-15 inhibitor ponsegromab in patients with cancer and cachexia: Safety, tolerability, and exploratory measures of efficacy

Cancer research (Chicago, Ill.), 2023-04, Vol.83 (8_Supplement), p.CT108-CT108

2023

Volltextzugriff (PDF)

Pharmacokinetics and pharmacodynamics of bococizumab, a monoclonal antibody to PCSK 9, after single subcutaneous injection at three sites [ NCT 02043301]

Cardiovascular therapeutics, 2017-10, Vol.35 (5)

2017

Volltextzugriff (PDF)

The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model

Drug metabolism and disposition, 2005-01, Vol.33 (1), p.165

2005

Volltextzugriff (PDF)

1 – 25 von 111

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(108)
Mit Volltextzugriff
(100)

Publikationsform

Artikel
(110)
Buchkapitel
(1)

Sprache

Englisch
(111)
Japanisch
(16)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)
... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Results of Bococizumab, A Monoclonal Antibody Against Proprotein Convertase Subtilisin/Kexin Type 9, from a Randomized, Placebo-Controlled, Dose-Ranging Study in Statin-Treated Subjects With Hypercholesterolemia

Population PK/PD modeling of low‐density lipoprotein cholesterol response in hypercholesterolemic participants following administration of bococizumab, a potent anti‐PCSK9 monoclonal antibody

Genome-wide pharmacogenetics of anti-drug antibody response to bococizumab highlights key residues in HLA DRB1 and DQB1

Superselective Chemoembolization of HCC: Comparison of Short-term Safety and Efficacy between Drug-eluting LC Beads, QuadraSpheres, and Conventional Ethiodized Oil Emulsion

MET Receptor Sequence Variants R970C and T992I Lack Transforming Capacity

Effects of Hepatic Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites

Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites

A Phase Ib First-In-Patient Study Assessing the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Ponsegromab in Participants with Cancer and Cachexia

Pharmacokinetics and pharmacodynamics of bococizumab, a monoclonal antibody to PCSK9, after single subcutaneous injection at three sites [NCT 02043301]

Assessing the Potential Risk of Cross-Reactivity Between Anti-Bococizumab Antibodies and Other Anti-PCSK9 Monoclonal Antibodies

Comparative Pharmacokinetics and Pharmacodynamics of Bococizumab Following a Single Subcutaneous Injection Using Drug Substance Manufactured at Two Sites or Administration via Two Different Devices

Quantitative PK–PD Model-Based Translational Pharmacology of a Novel Kappa Opioid Receptor Antagonist Between Rats and Humans

Improved preclinical cardiovascular therapeutic indices with long-term inhibition of norepinephrine reuptake using reboxetine

Dose-escalating study of the pharmacokinetics and tolerability of fesoterodine in children with overactive bladder

Pharmacokinetic/pharmacodynamic analysis of β-amyloid response following modulation of the gamma secretase enzyme

Pharmacokinetic and pharmacodynamic evaluation of PF-04360365, a humanized monoclonal anti-amyloid antibody, in young and aged cynomolgus monkeys

PF-04447943, a novel PDE9A inhibitor, increases cGMP levels in cerebrospinal fluid: Translation from non-clinical species to healthy human volunteers

Aβ variability and effect of gamma secretase inhibition on cerebrospinal fluid levels of Aβ in healthy volunteers

Lack of critical involvement of endothelial nitric oxide synthase in vascular nitrate tolerance in mice

H3 receptor antagonism increases methylhistamine levels in the cerebrospinal fluid of dogs and healthy human volunteers

Pharmacodynamics of in vivo nitroglycerin tolerance in normal conscious rats: effects of dose and dosing protocol

Prazosin Potentiates the Acute Hypotensive Effects of Nitroglycerin but Does Not Attenuate Nitrate Tolerance in Normal Conscious Rats

Abstract CT108: First-in-patient study of the GDF-15 inhibitor ponsegromab in patients with cancer and cachexia: Safety, tolerability, and exploratory measures of efficacy

Pharmacokinetics and pharmacodynamics of bococizumab, a monoclonal antibody to PCSK 9, after single subcutaneous injection at three sites [ NCT 02043301]

The impact of P-glycoprotein on the disposition of drugs targeted for indications of the central nervous system: evaluation using the MDR1A/1B knockout mouse model

Suchergebnisse filtern